RecruitingPhase 4NCT07587658
This After Market Study is Seeing if Dupilumab Plus Usual Standard of Care (SOC) is Better Than Usual Care Alone for Adult Participants After a Severe Chronic Obstructive Pulmonary Disease (COPD) Flare-Up Requiring Hospitalization
Sponsor: Regeneron Pharmaceuticals
Mullica Hill, NJ